Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride

被引:40
作者
Riccardi, Patrizia [1 ]
Baldwin, Ron [1 ]
Salomon, Ronald [2 ]
Anderson, Sharlet [2 ]
Ansari, Mohammad S. [1 ]
Li, Rui [1 ,3 ]
Dawant, Benoit [3 ]
Bauernfeind, Amy [2 ]
Schmidt, Dennis [2 ]
Kessler, Robert [1 ,2 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Radiol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Psychiat, Nashville, TN USA
[3] Vanderbilt Univ, Dept Comp Sci, Nashville, TN 37235 USA
关键词
18F] fallypride; alpha-methyl-para-tyrosine (AMPT); challenge; dopamine; dopamine D-2 receptors; humans; PET;
D O I
10.1016/j.biopsych.2007.03.022
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: This study examined whether positron emission tomography (PET) studies with [F-18] fallypride performed before and after alpha-methyl-para-tyrosine (AMPT) administration can be used to estimate baseline dopamine (DA) D-2 receptor occupancy in striatal and extrastriatal regions. Methods: Six normal subjects underwent PET with [F-18] fallypride before and after administration of AMPT. The DA D2 receptor binding potentials (bp) were calculated with the reference region method. Percent changes in bp in striatal and extrastriatal regions were calculated with both region-of-interest analysis and on a voxel by voxel basis with parametric images of DA D-2 receptor levels. Results: The results of the current study indicate that AMPT treatment significantly increased the bp in the caudate, putamen, ventral striatum, and substantia nigra. A trend level increase was seen in the medial thalamus. Conclusions: This study demonstrates that PET with [F-18] fallypride can be used to estimate baseline DA D, receptor occupancy in striatal and extrastriatal regions.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 34 条
[1]   Increased baseline occupancy of D2 receptors by dopamine in schizophrenia [J].
Abi-Dargham, A ;
Rodenhiser, J ;
Printz, D ;
Zea-Ponce, Y ;
Gil, R ;
Kegeles, LS ;
Weiss, R ;
Cooper, TB ;
Mann, JJ ;
Van Heertum, RL ;
Gorman, JM ;
Laruelle, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) :8104-8109
[2]  
Cragg SJ, 1997, J NEUROSCI, V17, P5738
[3]   IMPROVED ASSESSMENT OF SIGNIFICANT ACTIVATION IN FUNCTIONAL MAGNETIC-RESONANCE-IMAGING (FMRI) - USE OF A CLUSTER-SIZE THRESHOLD [J].
FORMAN, SD ;
COHEN, JD ;
FITZGERALD, M ;
EDDY, WF ;
MINTUN, MA ;
NOLL, DC .
MAGNETIC RESONANCE IN MEDICINE, 1995, 33 (05) :636-647
[4]   Imaging extrastriatal dopamine D2 receptor occupancy by endogenous dopamine in healthy humans [J].
Fujita, M ;
Verhoeff, NPLG ;
Varrone, A ;
Zoghbi, SS ;
Baldwin, RM ;
Jatlow, PA ;
Anderson, GM ;
Seibyl, JP ;
Innis, RB .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 387 (02) :179-188
[5]   GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys [J].
Gerhardt, GA ;
Cass, WA ;
Huettl, P ;
Brock, S ;
Zhang, ZM ;
Gash, DM .
BRAIN RESEARCH, 1999, 817 (1-2) :163-171
[6]   Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys [J].
Gerhardt, GA ;
Cass, WA ;
Yi, A ;
Zhang, ZM ;
Gash, DM .
JOURNAL OF NEUROCHEMISTRY, 2002, 80 (01) :168-177
[7]  
Goldman-Rakic P S, 1998, Adv Pharmacol, V42, P707
[8]   The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia [J].
Gründer, G ;
Landvogt, C ;
Vernaleken, I ;
Buchholz, HG ;
Ondracek, J ;
Siessmeier, T ;
Härtter, S ;
Schreckenberger, M ;
Stoeter, P ;
Hiemke, C ;
Rösch, F ;
Wong, DF ;
Bartenstein, P .
NEUROPSYCHOPHARMACOLOGY, 2006, 31 (05) :1027-1035
[9]   Distribution of dopamine D3 receptor expressing neurons in the human forebrain:: Comparison with D2 receptor expressing neurons [J].
Gurevich, EV ;
Joyce, JN .
NEUROPSYCHOPHARMACOLOGY, 1999, 20 (01) :60-80
[10]  
Kegeles LS, 2001, J NUCL MED, V42, p16P